OncoSil approved for Innovation Funding (NUB) in Germany
Filed with ASX · · 3 pages · English
✓ The Institute for the Hospital Remuneration System (InEK) has granted the OncoSil device with a“Positive Status 1”classification; ✓ 25 leading university hospital sites in Germany submitted requests for innovation funding (NUB) for the OncoSil device; ✓ Hospitals which submitted NUB applications can now individually negotiate with Statutory TM Health Insurance providers (“Sickness Funds”) for re
Earlier from OncoSil Medical
- PanCO Clinical Study on OncoSil Published in ESMO Open
- 2021 AGM CEO Presentation
- Receipt of $1.077m R&D Tax Incentive Refund
- OncoSil TGA regulatory update
- OncoSil receives regulatory approval from Hong Kong
Later from OncoSil Medical
- Half Yearly Report Results
- Fully-Funded Trial Approved In Germany
- First Commerical Pancreas Treatment In Spain
- OncoSil Signs Commercial Agreement With Hospital In Spain
- OncoSil Launches $10m Capital Raising
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical